Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Chief Development Officer | April 22, 2019 | April 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date April 22, 2019 · Filed April 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 222,991 |
Reported balance
After 2019-04-22 transaction · row 1
1 source rowRow 1 · 2019-04-22 · Grant · Acquired 222,991 · Balance 222,991 F1: This amount is comprised entirely of Restricted Stock Units which shall vest in equal installments over four years, with the first installment on April 22, 2020 and the last installment on April 22, 2023, subject to continued employment with the Company on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This amount is comprised entirely of Restricted Stock Units which shall vest in equal installments over four years, with the first installment on April 22, 2020 and the last installment on April 22, 2023, subject to continued employment with the Company on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2019 Filed Apr 24, 2019 20:25 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 222,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025841 · doc4.xml · nonDerivative · entry 1 Barrett John A · CIK 0001388395 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,991 F1 · shares: This amount is comprised entirely of Restricted Stock Units which shall vest in equal installments over four years, with the first installment on April 22, 2020 and the last installment on April 22, 2023, subject to continued employment with the Company on the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.